Search clinical trials for: Maximum Tolerated Dose

Total 21323 results

Boehringer Ingelheim

Completed

A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Active, not recruiting

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Healthy | Obesity

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test How Well Different Doses of BI 1323495 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated

Healthy

Belgium
NewAmsterdam Pharma

Active, not recruiting

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. (BROOKLYN)

Dyslipidemias | Hypercholesterolemia | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Familial Hypercholesterolemia | Metabolic Disease | High Cholesterol | Genetic Disease, Inborn | Lipid Metabolism Disorder

United States, Canada, Czechia, Georgia, Netherlands, Norway, Poland, South Africa, Spain, United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 765845 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

Depressive Disorder, Major

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy People

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

Healthy

Japan
Boehringer Ingelheim

Active, not recruiting

A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated

Healthy

Japan
Royal Marsden NHS Foundation Trust
AstraZeneca; Cancer Research UK; RM/ICR Biomedical Research Centre

Active, not recruiting

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours (Patriot)

Solid Tumour Refractory to Conventional Treatment

United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated

Healthy

Belgium
NewAmsterdam Pharma

Active, not recruiting

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY)

Dyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | High Cholesterol

United States, Poland, Denmark, Czechia, China, Netherlands, Japan, Georgia
Boehringer Ingelheim

Terminated

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Macular Degeneration

United Kingdom, United States
Case Comprehensive Cancer Center

Completed

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Acute Myeloid Leukemia | Multiple Myeloma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | Acute Biphenotypic Leukemia | Hodgkins Disease

United States
Boehringer Ingelheim

Terminated

A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)

Healthy

Netherlands
Cornerstone Pharmaceuticals

Completed

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Sarcoma, Clear Cell

United States
Vanquish Oncology, Inc.
University of Illinois at Chicago

Terminated

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

Glioblastoma Multiforme | Anaplastic Astrocytoma

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood

Healthy

Belgium
Bayer

Terminated

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (SEAL)

Acute Respiratory Distress Syndrome

United Kingdom, Spain, Germany, Czechia, Austria, Italy, France
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

Healthy

Japan
Bayer

Completed

Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels. (CONCORD)

Chronic Kidney Disease

Spain, Belgium, Austria, Germany, Bulgaria, Denmark, Italy, Israel, Sweden, Finland, Slovakia, Ukraine, Poland
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

Healthy

Germany
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Withdrawn

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

Osteosarcoma | Bone Metastases

United States
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Terminated

This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation

Non-cystic Fibrosis Bronchiectasis

United Kingdom, Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food

Healthy

Germany
Sunhawk Vision Biotech, Inc.

Completed

Phase 1 Study of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects

Myopia

Taiwan
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

Healthy

Belgium
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects

Healthy

Canada
Boehringer Ingelheim

Completed

A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Germany
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Withdrawn

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated

Healthy
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated

Healthy

Japan
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

Cytomegalovirus Infections
University of Maryland, Baltimore

Completed

Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine

Risk Reduction

United States

3

Subscribe